X

During the COVID-19 (Coronavirus) Pandemic: Your doctor may recommend switching you from a biologic to a topical treatment for your plaque psoriasis.1 You should not stop biologic therapy without consulting your doctor.

Reference: 1. American Academy of Dermatology Association. Aad.org. https://www.aad.org/member/practice/coronavirus/clinical-guidance/biologics. Accessed June 5, 2020.

FREQUENTLY ASKED QUESTIONS
upper open close icon
Why did my doctor prescribe ULTRAVATE® Lotion?

If you expressed a need to control your psoriasis symptoms quickly, clear or almost clear skin is possible in 2 weeks with ULTRAVATE® Lotion.1

Additional benefits of ULTRAVATE® Lotion include:

  • Moisturizes dry, thick plaques1,3-4,7
  • Spreadability of a lotion suitable for large body surfaces3,7
  • Appropriate treatment for elbows and knees1
upper open close icon
How do I use ULTRAVATE® Lotion?

Apply a thin layer of ULTRAVATE® Lotion to the affected skin twice daily for up to two weeks. Rub in gently.

Treatment beyond two weeks is not recommended.1

upper open close icon
What is the active ingredient in ULTRAVATE® Lotion?

Halobetasol propionate is the active ingredient in ULTRAVATE® Lotion. It is a corticosteroid that can help reduce the signs and symptoms of plaque psoriasis.1

upper open close icon
What makes ULTRAVATE® Lotion unique?

The active ingredient in ULTRAVATE® Lotion is halobetasol propionate, 0.05%, a corticosteroid. This moisturizing lotion is designed to reduce plaque psoriasis symptoms such as plaque buildup, inflammation, scaling, and dryness in 2 weeks1-3

upper open close icon
Are patient savings available?

Yes! Learn how you can pay less for your ULTRAVATE® Lotion prescriptions.

upper open close icon
Is ULTRAVATE® Lotion more moisturizing than ULTRAVATE® Cream?

Yes, ULTRAVATE® Lotion is easily spreadable while increasing absorption into the skin.1-3,7

SAVE ON ULTRAVATE® LOTION

References: 1. ULTRAVATE® Lotion [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017. 2. National Psoriasis Foundation. Topical steroid potency chart. https://www.psoriasis.org/about-psoriasis/treatments/topicals/ steroids/potency-chart. Accessed October 25, 2019. 3. Grove G, Zerweck C, Houser T, et al. Occlusivity and moisturization potential of a new lotion formulation of halobetasol propionate, 0.05%. Poster presented at: 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC. 4. Pariser D, Bukhalo M, Guenthner S, et al. Two multicenter, randomized, double-blind, parallel group comparison studies of a novel enhanced lotion formulation of halobetasol propionate lotion, 0.05% versus its vehicle lotion in adult subjects with plaque psoriasis. J Drugs Dermatol. 2017;16(3):234-240. 5. Feldman SR. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr Ther Res Clin Exp. 2005;66(3):154-171. 6. InformedHealth.org. Eczema: steroids and other topical medications. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG). 2017. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK424899/. 7. Feldman SR. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr Ther Res Clin Exp. 2005;66(3):154-171.

INDICATIONS AND USAGE

ULTRAVATE (halobetasol propionate) Lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Effects on Endocrine System: Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic effects of topical corticosteroids may also include Cushing’s syndrome, hyperglycemia, and glucosuria. Systemic absorption may require evaluation for HPA axis suppression. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure. Children may be more susceptible to systemic toxicity when treated with topical steroids.

Local Adverse Reactions: Local adverse reactions with topical steroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection and miliaria. These may be more likely to occur with occlusive use, prolonged use or more potent corticosteroids, including ULTRAVATE.

Concomitant Skin Infections: Use an appropriate antimicrobial agent if a skin infection is present or develops.

Allergic Contact Dermatitis: Discontinue ULTRAVATE Lotion if allergic contact dermatitis is established.
In clinical trials the most common adverse reactions (≥1%) were telangiectasia, application site atrophy, and headache.

Please see the Full Prescribing Information for complete prescribing details.